Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

ClinicalTrials.gov ID: NCT03367572

Public ClinicalTrials.gov record NCT03367572. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

Study identification

NCT ID
NCT03367572
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
University of Rochester NCORP Research Base
Other
Enrollment
1,363 participants

Conditions and interventions

Interventions

  • Dexamethasone Drug
  • Laboratory Biomarker Analysis Other
  • Netupitant/Palonosetron Hydrochloride Drug
  • Olanzapine Drug
  • Placebo Other
  • Prochlorperazine Drug
  • Quality-of-Life Assessment Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 18, 2018
Primary completion
Apr 12, 2024
Completion
Apr 12, 2024
Last update posted
Sep 24, 2025

2018 – 2024

United States locations

U.S. sites
18
U.S. states
13
U.S. cities
18
Facility City State ZIP Site status
Hawaii MU NCORP Honolulu Hawaii 96813
Decatur Memorial Hospital Decatur Illinois 62526
Gulf South MU-NCORP New Orleans Louisiana 70112
Michigan Cancer Research Consortium Ann Arbor Michigan 48106
Cancer Research Consortium of West Michigan Grand Rapids Michigan 49503
Health Partners Inc Minneapolis Minnesota 55454
Cancer Research for the Ozarks NCORP Springfield Missouri 65804
Nevada Cancer Research Foundation NCORP Las Vegas Nevada 89106
University of Rochester NCORP Research Base Rochester New York 14642
Southeast Clinical Oncology Research Program Winston-Salem North Carolina 27104
Columbus NCORP Columbus Ohio 43215
Dayton Clinical Oncology Program Dayton Ohio 45459
Geisinger Cancer Institute NCORP Danville Pennsylvania 17822
Greenville NCORP Greenville South Carolina 29615
Upstate Carolina NCORP Spartanburg South Carolina 29303
Saint Vincent Hospital Cancer Center Green Bay Green Bay Wisconsin 54301
Gundersen Health System La Crosse Wisconsin 54601
Aurora NCORP Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03367572, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 24, 2025 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03367572 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →